 |
|
The Effects of Molar Sodium Lactate in Reversing the Cardiotoxic Effect of Hyperpotassemia
SAMUEL BELLET, M.D.;
FRED WASSERMAN, M.D.
AMA Arch Intern Med. 1957;100(4):565-581.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
The subject of hyperpotassemia has assumed considerable importance in recent years. An excess of potassium produces profound disturbances in the organism in general and the heart in particular. The condition can be diagnosed relatively simply by clinical means, including the electrocardiogram, and may be confirmed by chemical determination. Hyperpotassemia kills primarily as a result of its cardiac effect, and this can, in most cases, be reversed by the various methods to be described below. Early recognition and prompt institution of proper therapy are of primary importance. The presence of hyperpotassemia may be said in many instances to constitute an acute cardiac emergency.
The causes of hyperpotassemia include those conditions which lead to an increase in the extracellular potassium which the patient is unable to handle, generally because of renal insufficiency. The increase in extracellular potassium may be the result of the following factors: (a) increased tissue destruction, anoxia, the crush
. . . [Full Text PDF of this Article]
Author Affiliations
Philadelphia
Director, Division of Cardiology, Philadelphia General Hospital, and Director, Division of Cardiovascular Disease, Graduate Hospital of the University of Pennsylvania (Dr. Bellet); Fellow of the American Heart Association, Philadelphia General Hospital, and Instructor in Cardiology, University of Pennsylvania Graduate School of Medicine (Dr. Wasserman).
Footnotes
Submitted for publication Dec. 11, 1956.
From the Division of Cardiology of the Philadelphia General Hospital and the Graduate Hospital and Robinette Foundation of the University of Pennsylvania. This work was aided by grants from the U. S. Public Health Service (Grant H 146C7) and the Foundation for Cardiovascular Research. The molar sodium lactate used in this study was furnished by Eli Lilly & Company, Indianapolis.
|
